The report of cash and cash equivalents is a standard disclosure that provides investors with insight into the company's liquidity. While this information is important, it does not by itself indicate a change in the company's operations or prospects that would lead to a short-term price movement. Therefore, the impact is neutral, but the relevance is high as it pertains directly to Nemaura Medical.